Clinical trials: Clinical Efficacy
Solid Tumor
HS-IT201 Injection in the Treatment of Advanced Solid Tumors
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT201) after lymphodepletion preparative with fludarabine and cyclophosphamide…
- Trial name
- NCT06613152
- Testing
- HS-IT201 Injection
- Volunteers
- 9 people
- Sponsor
- Hangzhou Huasai Biomedicine Co., Ltd.
Influenza
A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
The pivotal Phase 3 trial plans to enroll a total of approximately 12,460 participants aged 50+ over two years. Participants will be immunized twice with the M-001 universal influenza vaccine candidate or placebo and then…
- Trial name
- NCT03450915
- Testing
- M-001, Saline
- Where
- 2 sites in Poland
- Volunteers
- 12,460 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of BEBT-209 in combination with fulvestrant in patients with HR+/HER2- locally…
- Trial name
- NCT06998108
- Testing
- BEBT-209 capsules, Fulvestrant Injection
- Where
- China
- Volunteers
- 330 people
- Sponsor
- BeBetter Med Inc
Advanced Malignant Solid Tumor, Advanced Lung Cancer
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness.
- Conditions
- Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT07110363
- Testing
- BT02
- Volunteers
- 58 people
- Sponsor
- Biotroy Therapeutics
Upper Limb Spasticity
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults
- Trial name
- NCT06783114
- Testing
- Recombinant Botulinum Toxin Type A for injection (YY001), BOTOX®
- Where
- 24 sites in China
- Volunteers
- 254 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Coronary Artery Disease
Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry
The e-Ultimaster will further validate the safety and efficacy of Ultimaster DES system in unselected patients representing everyday clinical practice.
- Trial name
- e-Ultimaster (NCT02188355)
- Where
- 462 sites in Argentina, Armenia and 48 more
- Volunteers
- 37,000 people
- Sponsor
- Terumo Europe N.V.
Arthritis, Rheumatoid
Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients
The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy of valdecoxib 10 mg QD versus…
- Trial name
- NCT00650455
- Testing
- valdecoxib, naproxen
- Where
- 55 sites in United States, Canada
- Volunteers
- 489 people
- Sponsor
- Pfizer
Blepharospasm
Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
The purpose of this study is to evaluate the Efficacy and Safety of NABOTA in treatment of essential blepharospasm
- Trial name
- NCT02947815
- Testing
- Clostridium Botulinum Toxin Type A
- Where
- South Korea
- Volunteers
- 234 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension
Recording of Physiological Data Via an Optical Sensor At the Fingertip Alongside with Double Auscultatory and Pulse Oximetry to Evaluate the Effectiveness of an Optical Blood Pressure Monitoring (OBPM)
The present study, OBPM_Calfree2024, with N = 85 participants minimum over 1 visit (lasting around 1h), has been designed to collect raw optical data with Aktiia.product-G2C Clinical investigational system together with several…
- Trial name
- NCT06368206
- Testing
- Investigational device Aktiia G2C, Marketed device used as reference for blood pressure monitoring: double auscultation cuff, Marketed device used as comparative device for blood pressure and pulse rate monitoring: Aktiia Bracelet G2
- Where
- Switzerland
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Aktiia SA
Hepatocellular Carcinoma (HCC)
NWRD06 DNA Plasmid for HCC After Curative Resection.
This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma…
- Trial name
- NCT07324304
- Testing
- NWRD06 administered by electroporation
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
Colonoscopy, Bowel Preparation
A Study to Evaluate the Safety and Effectiveness of MSP01-T for Bowel Cleansing Before a Colonoscopy
This study is being conducted to evaluate the safety and effectiveness of MSP01-T, a new bowel cleansing agent, in adults who are scheduled to undergo a colonoscopy.
- Trial name
- MSP01 (NCT07181148)
- Testing
- MSP01-R, MSP01-T
- Where
- South Korea
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Mather's Pharm. Co., Ltd.
Postsurgical Pain, Third Molar Extraction
Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction
The purpose of this study is to evaluate the efficacy of APSCTC compared to two active drugs in acute pain relief.
- Trial name
- CARLOTA (NCT04647435)
- Testing
- APSCTC, Toragesic®, Tramal®
- Where
- Brazil
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- Apsen Farmaceutica S.A.
Osteoarthritis of the Knee
To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee
This is a randomized, double-blind study to compare the efficacy and safety of LAYLA tablet and CENATONE tablet in the treatment of osteoarthritis of the knee.
- Trial name
- NCT02049606
- Testing
- LAYLA tablet, CENATONE tablet
- Where
- 6 sites in South Korea
- Volunteers
- 134 people
- Sponsor
- PMG Pharm Co., Ltd
Glaucoma, Ocular Hypertension
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of…
- Trial name
- NCT01254604
- Testing
- Preservative-Free Tafluprost or vehicle, Preservative-Free Timolol maleate
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH
Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy with Tamsulosin Monotherapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
- Trial name
- NCT02972268
- Testing
- Tamsulosin 0.2mg + Solifenacin 5mg
- Where
- South Korea
- Volunteers
- 780 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Acute Bronchitis
Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis
A Multicenter, Randomized, Double-blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis
- Trial name
- NCT07111468
- Testing
- YHP2401, YHR2402, YHR2403
- Where
- 11 sites in South Korea
- Volunteers
- 286 people
- Sponsor
- Yuhan Corporation
Allergy
Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis
The trial is performed to assess efficacy and safety of a recombinant grass Pollen allergen cocktail in allergic rhinoconjunctivitis
- Trial name
- NCT00309036
- Testing
- Recombinant grass pollen
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Copd, COPD Exacerbation
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.
Preferred pharmacological management for COPD according to the GOLD guidelines are the long-acting anticholinergic LAMAs (Long-Acting / Short-Acting Muscarinic Antagonists), and long-acting β 2-Agonists LABA (Long-acting LABA) /…
- Trial name
- ARGO (NCT05426915)
- Where
- Greece
- Volunteers
- 750 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Migraine, Headache
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
The purpose of this study is to evaluate the safety and efficacy of MK-6096 versus placebo for preventing migraines in participants with episodic migraine.
- Trial name
- NCT01513291
- Testing
- MK-6096
- Volunteers
- 237 people
- Sponsor
- Merck Sharp & Dohme LLC
Preoperative Sedation
The Study is Being Conducted to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Microneedles for Preoperative Sedation in Children
The study is being conducted to evaluate the efficacy, safety and the population pharmacokinetic characteristics of Dexmedetomidine Hydrochloride Microneedles for preoperative sedation in children
- Trial name
- NCT07168720
- Testing
- Dexmedetomidine hydrochloride Microneedles
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Guangzhou Novaken Pharm Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.